Hutchmed reported a Phase 3 success with sovleplenib in an autoimmune indication and said it will pursue a China filing based on the trial’s positive primary endpoint. The result revives an asset that had faced manufacturing or quality setbacks in another indication and positions Hutchmed to advance global development plans. Johnson & Johnson disclosed mid‑stage success with its monoclonal antibody Imaavy in lupus and is planning a late‑stage trial after the Phase 2 readout. Imaavy’s mid‑stage efficacy supports J&J’s strategy to broaden the antibody’s use across autoimmune diseases. The twin updates from Hutchmed and J&J reflect active late‑stage contestation in autoimmunity, where differentiated mechanisms and safety profiles will determine commercial positioning.